Aclidinium bromide for stable chronic obstructive pulmonary disease

Area of Science:

• Pulmonary Medicine
• Pharmacology

Background:

• Bronchodilators are key for stable COPD symptom relief.
• Aclidinium bromide, a long-acting muscarinic antagonist (LAMA), offers higher M3 selectivity and faster onset than tiotropium, but has a shorter duration.
• Its efficacy and safety compared to other bronchodilators in COPD management remain uncertain.

Purpose of the Study:

• To evaluate the efficacy and safety of aclidinium bromide in stable COPD patients.
• To compare aclidinium bromide against placebo, long-acting beta2-agonists (LABA), or other LAMAs.

Main Methods:

• Systematic review and meta-analysis of 12 multicenter randomized controlled trials (RCTs).
• Included 9547 participants with stable, moderate to severe COPD.
• Data extracted and analyzed using odds ratios and mean differences, with GRADE approach for evidence quality.

Main Results:

• Aclidinium bromide improved quality of life (SGRQ score reduction) and reduced hospitalizations for severe exacerbations compared to placebo.
• No significant differences were observed in all-cause mortality, exacerbations requiring oral steroids/antibiotics, or non-fatal serious adverse events versus placebo.
• Compared to tiotropium, no significant differences were found for exacerbations, hospitalizations, or serious adverse events.

Conclusions:

• Aclidinium bromide enhances quality of life and decreases COPD exacerbation-related hospitalizations.
• It does not significantly reduce mortality, serious adverse events, or exacerbations requiring medical treatment.
• Further research is needed to compare aclidinium bromide with other LAMAs and LABAs due to insufficient and low-quality data.